There is still an urgent need to develop nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) with a high-genetic barrier to resistance that facilitate patient adherence and allow durable suppression of HIV-1 replication. In this study, we describe the synthesis of a novel series of N-aminoimidazole (NAIM) analogs. Each of the NAIM analogs display potent activity against wild-type recombinant purified HIV-1 RT as well as RTs containing the K103N or Y181C resistance mutations. The analogs, however, do not exhibit significant antiviral activity in cell culture and were, in general, cytotoxic. Nevertheless, these data suggest that the NAIM backbone may provide a suitable scaffold from which inhibitors active against NNRTI-resistant HIV-1 could be developed.
There is still an urgent need to develop nonnucleoside reverse transcriptase (RT) inhibitors (pan class="Chemical">NNRTI) with a high-genetic barrier to resistance that facilitate patient adherence and allow durable suppression of HIV-1 replication. In this study, we describe the synthesis of a novel series of N-aminoimidazole (NAIM) analogs. Each of the NAIM analogs display potent activity against wild-type recombinant purified HIV-1 RT as well as RTs containing the K103N or Y181C resistance mutations. The analogs, however, do not exhibit significant antiviral activity in cell culture and were, in general, cytotoxic. Nevertheless, these data suggest that the NAIM backbone may provide a suitable scaffold from which inhibitors active against NNRTI-resistant HIV-1 could be developed.
Authors: Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2006 Aug-Sep
Authors: A L Hopkins; J Ren; R M Esnouf; B E Willcox; E Y Jones; C Ross; T Miyasaka; R T Walker; H Tanaka; D K Stammers; D I Stuart Journal: J Med Chem Date: 1996-04-12 Impact factor: 7.446
Authors: Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191
Authors: J Ren; C Nichols; L Bird; P Chamberlain; K Weaver; S Short; D I Stuart; D K Stammers Journal: J Mol Biol Date: 2001-09-28 Impact factor: 5.469
Authors: Nicolas Sluis-Cremer; Dianna Koontz; Leda Bassit; Brenda I Hernandez-Santiago; Mervi Detorio; Kim L Rapp; Franck Amblard; Lavanya Bondada; Jason Grier; Steven J Coats; Raymond F Schinazi; John W Mellors Journal: Antimicrob Agents Chemother Date: 2009-07-13 Impact factor: 5.191
Authors: T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191